Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

Cited In for PubMed (Select 17194588)

1.

Structural basis and biological consequences for JNK2/3 isoform selective aminopyrazoles.

Park H, Iqbal S, Hernandez P, Mora R, Zheng K, Feng Y, LoGrasso P.

Sci Rep. 2015 Jan 27;5:8047. doi: 10.1038/srep08047.

2.

Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.

Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso PV, Feng Y.

J Med Chem. 2014 Dec 11;57(23):10013-30. doi: 10.1021/jm501256y. Epub 2014 Nov 21.

PMID:
25393557
3.

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.

Dranchak P, MacArthur R, Guha R, Zuercher WJ, Drewry DH, Auld DS, Inglese J.

PLoS One. 2013;8(3):e57888. doi: 10.1371/journal.pone.0057888. Epub 2013 Mar 7.

4.

Discovery of potent and selective covalent inhibitors of JNK.

Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS.

Chem Biol. 2012 Jan 27;19(1):140-54. doi: 10.1016/j.chembiol.2011.11.010.

5.

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.

Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ.

Br J Pharmacol. 2012 Jun;166(3):858-76. doi: 10.1111/j.1476-5381.2012.01859.x. Review.

6.

Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.

De SK, Barile E, Chen V, Stebbins JL, Cellitti JF, Machleidt T, Carlson CB, Yang L, Dahl R, Pellecchia M.

Bioorg Med Chem. 2011 Apr 15;19(8):2582-8. doi: 10.1016/j.bmc.2011.03.017. Epub 2011 Mar 12.

7.

Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.

He Y, Kamenecka TM, Shin Y, Song X, Jiang R, Noel R, Duckett D, Chen W, Ling YY, Cameron MD, Lin L, Khan S, Koenig M, LoGrasso PV.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1719-23. doi: 10.1016/j.bmcl.2011.01.079. Epub 2011 Jan 22.

8.

Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.

Noël R, Shin Y, Song X, He Y, Koenig M, Chen W, Ling YY, Lin L, Ruiz CH, LoGrasso P, Cameron MD, Duckett DR, Kamenecka TM.

Bioorg Med Chem Lett. 2011 May 1;21(9):2732-5. doi: 10.1016/j.bmcl.2010.11.104. Epub 2010 Dec 1.

9.

Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.

Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Habel J, Laughlin JD, Chambers J, Figuera-Losada M, Cameron MD, Lin L, Ruiz CH, LoGrasso PV.

J Med Chem. 2010 Jan 14;53(1):419-31. doi: 10.1021/jm901351f. Erratum in: J Med Chem. 2010 Feb 25;53(4):1882.

10.

Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.

Shin Y, Chen W, Habel J, Duckett D, Ling YY, Koenig M, He Y, Vojkovsky T, LoGrasso P, Kamenecka TM.

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3344-7. doi: 10.1016/j.bmcl.2009.03.086. Epub 2009 Mar 26.

11.

Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.

Kamenecka T, Habel J, Duckett D, Chen W, Ling YY, Frackowiak B, Jiang R, Shin Y, Song X, LoGrasso P.

J Biol Chem. 2009 May 8;284(19):12853-61. doi: 10.1074/jbc.M809430200. Epub 2009 Mar 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk